<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123916</url>
  </required_header>
  <id_info>
    <org_study_id>BEN01</org_study_id>
    <secondary_id>CONEP-11394</secondary_id>
    <nct_id>NCT00123916</nct_id>
  </id_info>
  <brief_title>BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease</brief_title>
  <acronym>BENEFIT</acronym>
  <official_title>Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Dante Pazzanese de Cardiologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for
      60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment -
      period adjusted according to the patient's body weight to a total minimum dose of 12g
      (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces
      morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC).

      The BENEFIT study is being conducted by the Population Health Research Institute (in
      Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil)
      together with a Steering Committee, and an independent Safety Monitoring Board.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized double-blind controlled clinical trial investigating the role of benznidazole in
      patients with chronic Chagas' heart disease.

      Chagas disease has 3 phases: acute, undetermined and chronic phases. There are no clinical
      trials up to date that have investigated the use of antiparasitic drugs in patients that are
      in the chronic phase.

      This study will evaluate the efficacy and safety of benznidazole (an antiparasitic drug) in
      patients with chronic Chagas' heart disease. Evaluate if benznidazole, an antiparasite drug,
      given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose
      of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body
      weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g
      (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas'
      Cardiomyopathy (CCC). It will be developed in 49 study centres in Argentina,
      Bolivia,Brazil,Colombia, and El Salvador - countries with high incidence of Chagas Disease.

      The Pilot study is evaluating if benznidazole is effective in producing parasitic cure (PCR
      negativization or reducing parasitic load) in chronic Chagas Disease as well as assessing the
      feasibility of conducting a large trial in chronic Chagas Disease in South America.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of First of cardiovascular events: Death, Resuscitated Cardiac Arrest, Sustained VentricularTachycardia, New/worsening Heart Failure, New Pacemaker/ICD, Stroke/TIA or other Embolic Events, Cardiac Transplant.</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Composite cardiovascular outcome,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New development of any of the following echo changes, segmental wall motion abnormalities, ventricular aneurysm, reduction in LV ejection fraction &gt;5%, increase in LVDD&gt; 5 mm compared to baseline.</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New 12 lead ECG alterations (complete bundle branch block, fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc).</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of NYHA functional class by at least one category</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New 12 lead electrocardiogram (ECG) alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc.)</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of New York Heart Association (NYHA) functional class by at least one category</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the efficacy of benznidazole in patients with Chronic Chagas heart disease based on a 50% reduction in both qualitative and quantitative PCR.</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Polymerase Chain Reaction study on patient's blood samples and report negativization at the end of treatment, 2Y and final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of benznidazole</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2854</enrollment>
  <condition>Chagas Disease</condition>
  <condition>Trypanosomiasis</condition>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Benznidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 - 80 days (according to body weight) treatment with benznidazol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 - 80 days (according to body weight) treatment with matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benznidazole</intervention_name>
    <description>Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)</description>
    <arm_group_label>Benznidazole</arm_group_label>
    <other_name>Rochagan/LaFepe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Rochagan/LaFepe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting patients (between 18 and 75 years of age) with serological evidence of
             Chagas infection (any combination of 2 positive tests) and that have one or more of
             the following:

          -  Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left
             anterior or posterior fascicular block; ventricular premature beat; first degree
             atrioventricular [AV] block; Mobitz type I AV block; sinus bradycardia; primary ST-T
             changes; abnormal Q waves; low voltage QRS; or atrial fibrillation);

          -  Abnormal ECG (Mobitz type II, advanced or third degree AV block);

          -  Increased cardiothoracic ratio (&gt; 0.50);

          -  Complex ventricular arrythmias on 24 hour ambulatory ECG monitoring;

          -  Evidence of regional wall motion abnormality or reduced global left ventricular
             systolic function or increased left ventricular and diastolic diameter on 2D-Echo.

        Exclusion Criteria:

        Patients will be excluded if having:

          -  NYHA heart failure class IV or decompensated heart failure

          -  Evidence of concomitant coronary artery disease (CAD) or other etiology of dilated
             cardiomyopathy

          -  Previous treatment with antitrypanosomal agents or an accepted indication for
             antiparasitic therapy

          -  Inability to comply with follow-up visits

          -  History of severe alcohol abuse within 2 years

          -  Known chronic renal or hepatic insufficiency or hepatic insufficiency

          -  Pregnancy or breast feeding

          -  Megaesophagus with swallowing impairment

          -  Other severe disease significantly curtailing life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Morillo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Population Health Research Institute - McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Antonio Marin-Neto, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salim Yusuf, MD, DPh</last_name>
    <role>Study Chair</role>
    <affiliation>Population Health Research Institute - McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Sosa-Estani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Argentina National Coordinator - CenDIE, Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Rosas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Clinica Shaio, Bogota, Colombia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BENEFIT Ivestigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Apital Federal</state>
        <zip>3556</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Belén De Escobar</city>
        <state>Buenos Aires</state>
        <zip>1753</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Isidro Casanova</city>
        <state>Buenos Aires</state>
        <zip>1282</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>San Juan</city>
        <state>Buenos Aires</state>
        <zip>1625</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Santiago del Estero</city>
        <state>Buenos Aires</state>
        <zip>4200</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Santiago del Estero</city>
        <state>Buenos Aires</state>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>1063</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>San Fernando del Valle de Catamarca</city>
        <state>Catamarca</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Charata</city>
        <state>Chaco</state>
        <zip>H3730AVI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Paraná</city>
        <state>Entre Rios</state>
        <zip>3100</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <state>General Rodríguez Partido</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>San Salvador de Jujuy</city>
        <state>Jujuy</state>
        <zip>4600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Corrientes</city>
        <state>Rosario, Santa Fe</state>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Añatuya</city>
        <state>Santiago Del Estero</state>
        <zip>3760</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Santiago Del Estero</city>
        <state>Sgo. Del Estero</state>
        <zip>4200</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Salta</city>
        <zip>A4406CLA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Tupiza</city>
        <state>Potosi</state>
        <country>Bolivia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahaia</state>
        <zip>40050-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahaia</state>
        <zip>40110-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahaia</state>
        <zip>40425-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Carmo</city>
        <state>Belo Horizonte</state>
        <zip>30130-690</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Brasília</city>
        <state>Brazilian Federal District</state>
        <zip>70658-700</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74110-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74110-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74605-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Uberlandia</city>
        <state>MG</state>
        <zip>38025-440</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Uberlândia</city>
        <state>MG</state>
        <zip>38400-299</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Uberaba</city>
        <state>Minas Gerais</state>
        <zip>38010-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50100-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Pelotas</city>
        <state>Rio Grande Do Sul</state>
        <zip>96015-290</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13059-740</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15015-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Votuporanga</city>
        <state>São Paulo</state>
        <zip>15500-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01417 010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>Bogota</city>
        <state>Bogotá</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Investigational Site</name>
      <address>
        <city>San Gil</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BENEFIT Ivestigational Site</name>
      <address>
        <city>San Salvador</city>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bolivia</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>El Salvador</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.phri.ca</url>
    <description>Population Health Research Institute</description>
  </link>
  <reference>
    <citation>Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S; BENEFIT Investigators. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J. 2008 Jul;156(1):37-43. doi: 10.1016/j.ahj.2008.04.001.</citation>
    <PMID>18585495</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 21, 2005</study_first_submitted>
  <study_first_submitted_qc>July 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2005</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>Salim Yusuf's office</investigator_full_name>
    <investigator_title>Principal Co-Investigator</investigator_title>
  </responsible_party>
  <keyword>Chagas Disease</keyword>
  <keyword>Trypanosomiasis</keyword>
  <keyword>Benznidazole</keyword>
  <keyword>Chronic Heart disease</keyword>
  <keyword>Trypanosoma Cruzi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
    <mesh_term>Trypanosomiasis</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzonidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

